PD184352 (CI-1040)

Catalog No.S1020

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Cited by 48 Publications

Cancer Cell, 2016, 10.1016/j.ccell.2016.01.006

PubMed: 26859455 ( click the link to review the publication )

Cancer Discov, 2013, 3(9):1058-71

PubMed: 23744832 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Mol Cell, 2019, 74(5):1086-1102.e5

PubMed: 31101498 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1212-1226

PubMed: 28087600 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):19

PubMed: 28100259 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):658-68

PubMed: 26189368 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2016, 20(10):1961-8

PubMed: 27249593 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3016-31

PubMed: 24937430 ( click the link to review the publication )

EMBO Mol Med, 2014, 7(1):102-23

PubMed: 25550395 ( click the link to review the publication )

Cancer Lett, 2014, 347(2):212-24

PubMed: 24576622 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

FASEB J, 2014, 28(10):4551-62

PubMed: 25008089 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114389

PubMed: 25486532 ( click the link to review the publication )
Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

PLoS One, 2013, 8(10):e76505

PubMed: 24124570 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68378

PubMed: 23874604 ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

Oncogene, 2012, 32(38):4480-9

PubMed: 23108403 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(4):R111

PubMed: 22817771 ( click the link to review the publication )

Neoplasia, 2012, 14(4):283-96

PubMed: 22577344 ( click the link to review the publication )

J Biol Chem, 2012, 288(6):4174-93

PubMed: 23255592 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27863-75

PubMed: 22685289 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(6):1056-73

PubMed: 22570334 ( click the link to review the publication )

Int J Parasitol, 2012, 40(5):555-67

PubMed: 19887070 ( click the link to review the publication )

J Cell Biochem, 2012, 113(1):360-71

PubMed: 21928324 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

J Exp Med, 2011, 208(9):1889-900

PubMed: 21825016 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(39):16392-7

PubMed: 21930937 ( click the link to review the publication )

Cell Death Dis, 2011, 2:e124

PubMed: 21368895 ( click the link to review the publication )

Dis Model Mech, 2011, 4(3):393-9

PubMed: 21263000 ( click the link to review the publication )

Antiviral Res, 2011, 92(2):195-203

PubMed: 21854809 ( click the link to review the publication )

Toxicol Sci, 2011, 123(2):542-9

PubMed: 21742783 ( click the link to review the publication )

Front Physiol, 2011, 2:71

PubMed: 22028692 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Features

First MEK inhibitor to begin clinical development.

Targets

MEK1 ^[1] (Cell-free assay)	MEK2 ^[1] (Cell-free assay)
17 nM	17 nM

In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. ^[1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. ^[2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. ^[3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
H9	NVKzfYhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LaXWlEPTB;MD6wNlI4PiEQvF2=	MmXjV2FPT0WU
CHP-212	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMEK4PFUh\|ryP	MoXvV2FPT0WU
EoL-1-cell	NHq3dIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIr5eW9KSzVyPUCuNFQyPTJizszN	MWjTRW5ITVJ?
DU-4475	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDYTWM2OD1yLkC3OVk6KM7:TR?=	NHLacYdUSU6JRWK=
MMAC-SF	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TWU2lEPTB;MD6xNFk4PCEQvF2=	M4Tw[3NCVkeHUh?=
AGS	NFjWZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfsTWM2OD1yLkGxO\|E{KM7:TR?=	MlHxV2FPT0WU
M14	MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjwcGhKSzVyPUCuNVU1PjhizszN	NWTYeVdtW0GQR1XS
CP50-MEL-B	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMUeyOVQh\|ryP	NUPFe2IzW0GQR1XS
C32	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jyUWlEPTB;MD6xPVA4OiEQvF2=	MXzTRW5ITVJ?
KMOE-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMUm3PVUh\|ryP	M1HYbHNCVkeHUh?=
A101D	NWrXdIpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrGTWM2OD1yLkKxOEDPxE1?	NEO3TphUSU6JRWK=
KM12	NXX4dWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVy0OGk5UUN3ME2wMlI1ODV5IN88US=>	MWfTRW5ITVJ?
HSC-4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwMkSzPVUh\|ryP	NGHWfnVUSU6JRWK=
NOMO-1	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2T3VmlEPTB;MD6yOVc1OiEQvF2=	MlHOV2FPT0WU
MZ7-mel	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPRU3ZKSzVyPUCuNlY{PCEQvF2=	NFG4TZNUSU6JRWK=
ACN	NUXPWGRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Lqb2lEPTB;MD6yOlc{PyEQvF2=	NHvBdINUSU6JRWK=
MEL-HO	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnW0TWM2OD1yLkK3OlUzKM7:TR?=	NUfu[W9jW0GQR1XS
BHT-101	M1nMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDYV3FKSzVyPUCuNlg3ODZizszN	NIrmbWlUSU6JRWK=
SK-MEL-28	MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XaPGlEPTB;MD6zNFQxQSEQvF2=	NECyUnVUSU6JRWK=
KG-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwM{C2Olgh\|ryP	NIq4dZZUSU6JRWK=
COLO-679	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;I[mlEPTB;MD6zNlczKM7:TR?=	MnTrV2FPT0WU
SK-MEL-24	M3LuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPYVnFKSzVyPUCuN\|I5OTNizszN	M2O3TnNCVkeHUh?=
G-361	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWewWmFCUUN3ME2wMlM3Pzl3IN88US=>	M4XTV3NCVkeHUh?=
KY821	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTvTWM2OD1yLkO3PVEh\|ryP	Mn;PV2FPT0WU
KASUMI-1	MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXPTWM2OD1yLkO5PUDPxE1?	MVjTRW5ITVJ?
HL-60	NYLmd\|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jvV2lEPTB;MD60NVExPyEQvF2=	MUPTRW5ITVJ?
K5	NWfKR2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwNEOxNVch\|ryP	MmfnV2FPT0WU
KU812	NWDuS\|FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLXPI1OUUN3ME2wMlQ2Ojl7IN88US=>	NHrxVnFUSU6JRWK=
SH-4	NFTaPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\UTWM2OD1yLkS2NlU3KM7:TR?=	MUDTRW5ITVJ?
HTC-C3	NYDHTVFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;TTWM2OD1yLkS2OVMyKM7:TR?=	MlWwV2FPT0WU
CP66-MEL	NVTnVYhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwNEi4NFkh\|ryP	M1jtfnNCVkeHUh?=
WM-115	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwNEmyOVch\|ryP	NGG1[llUSU6JRWK=
A2780	NWfpc\|l5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfzTWM2OD1yLkS5PFI{KM7:TR?=	M3LaWXNCVkeHUh?=
P12-ICHIKAWA	NXjYcYR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\OWGRKSzVyPUCuOlEzOjFizszN	M4Hne3NCVkeHUh?=
HMV-II	NX;FSYdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLxfoVnUUN3ME2wMlY1PDZ3IN88US=>	M1LFeHNCVkeHUh?=
HT-144	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGW1bFlKSzVyPUCuOlQ3PTdizszN	MojDV2FPT0WU
LB2518-MEL	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwN{G2N\|Ih\|ryP	M3\JOXNCVkeHUh?=
NCI-SNU-1	NFHveGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1z6O2lEPTB;MD63OVQ{OyEQvF2=	MX\TRW5ITVJ?
C2BBe1	NW\xUJQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwOEGwNlMh\|ryP	M{\YTnNCVkeHUh?=
PSN1	NFLUPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXqSG0zUUN3ME2wMlk3OTl4IN88US=>	NYTQcYU4W0GQR1XS
UACC-257	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwOU[0O\|Mh\|ryP	MUfTRW5ITVJ?
RVH-421	NUTHVJAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;CPJRKSzVyPUCuPVcyQCEQvF2=	NXLVSWhWW0GQR1XS
GP5d	MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwOUizNFgh\|ryP	NF65XldUSU6JRWK=
TYK-nu	M2joW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzYTWM2OD1zLkCzNVczKM7:TR?=	M3z0S3NCVkeHUh?=
SK-N-AS	NGG3PZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTFwMEe5OFch\|ryP	MYnTRW5ITVJ?
SW620	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnPO5UzUUN3ME2xMlE{PTN2IN88US=>	MYPTRW5ITVJ?
HuP-T4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX33eo5HUUN3ME2xMlE5OzV7IN88US=>	MnO1V2FPT0WU
A549	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTFwMUm1O\|Yh\|ryP	NFnyS4ZUSU6JRWK=
Mewo	NXnKOWd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYm3RmlQUUN3ME2xMlIxOjd4IN88US=>	M3vFPXNCVkeHUh?=
ONS-76	NXHSS5k4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3niZWlEPTB;MT6yNlA1QSEQvF2=	NUDIcmRyW0GQR1XS
SK-MEL-1	M3PJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfy[JZpUUN3ME2xMlI{PDF7IN88US=>	Ml7YV2FPT0WU
RCM-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofGTWM2OD1zLkK0NFQ4KM7:TR?=	M2na[nNCVkeHUh?=
H-EMC-SS	M2rjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTFwMkm2NFgh\|ryP	NVi1OoNXW0GQR1XS
NCI-H2291	NUW5flZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLhTWM2OD1zLkOyOVM3KM7:TR?=	Mn;GV2FPT0WU
SW1463	NGLpXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwM{O3NlEh\|ryP	NXHBNHpPW0GQR1XS
LS-411N	M1zmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHLfFVKSzVyPUGuOFA2OTdizszN	M3Lhe3NCVkeHUh?=
BV-173	NX7KVnZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fIRmlEPTB;MT60OFAyPSEQvF2=	MXvTRW5ITVJ?
LS-513	MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4[wb2lEPTB;MT60OVE6OiEQvF2=	NEfBeohUSU6JRWK=
LoVo	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn24TWM2OD1zLkS2N\|k6KM7:TR?=	NGDxW5FUSU6JRWK=
HO-1-N-1	MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInTfI9KSzVyPUGuOVE3OzRizszN	M3zD[3NCVkeHUh?=
ML-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTFwNUK4Olgh\|ryP	NWXMOIRxW0GQR1XS
NCI-H1437	NWrtXW5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTFwNUWyO\|Uh\|ryP	MmLyV2FPT0WU
SW1116	NEnKNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfvd2hlUUN3ME2xMlU3Ozl6IN88US=>	M1i5OnNCVkeHUh?=
A4-Fuk	NYPMW5JvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHKTWM2OD1zLkW3NFQ2KM7:TR?=	MkXnV2FPT0WU
HD-MY-Z	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTFwNUezO\|Yh\|ryP	MnLPV2FPT0WU
SK-MEL-2	NYToPHJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfNTWM2OD1zLkW3OFU6KM7:TR?=	MXjTRW5ITVJ?
RT-112	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFmxdHpKSzVyPUGuOVg6PTJizszN	M2\vXnNCVkeHUh?=
COLO-829	Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPqTWM2OD1zLk[yNlMzKM7:TR?=	NFL2d5hUSU6JRWK=
OVCAR-5	NWnQXIk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTFwN{e2PFch\|ryP	NF74dWtUSU6JRWK=
NB69	NVrpVYZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHxTWM2OD1zLke4OFY6KM7:TR?=	NUHSOXJLW0GQR1XS
NCI-H292	MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nONGlEPTB;MT64OlY6QSEQvF2=	MWTTRW5ITVJ?
LOXIMVI	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjxcnZKSzVyPUGuPFk1OjdizszN	MkPWV2FPT0WU
BPH-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvnVnBnUUN3ME2xMlg6PTlzIN88US=>	NXe0R5lPW0GQR1XS
A375	MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLZTlNKSzVyPUGuPFk4OTRizszN	M3fRVHNCVkeHUh?=
LCLC-97TM1	MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFwOUKyOVYh\|ryP	MX7TRW5ITVJ?
RXF393	NFHVe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTFwOUe4PFch\|ryP	NVv1NFFEW0GQR1XS
HCC70	NWr4cnRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLnWZlrUUN3ME2yMlAzPDJ4IN88US=>	MYDTRW5ITVJ?
EM-2	M4W4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnacmszUUN3ME2yMlA4OTl6IN88US=>	M17Q[HNCVkeHUh?=
MZ2-MEL	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTnTWM2OD1{LkGxNVI4KM7:TR?=	NHzo[3lUSU6JRWK=
HN	M37yOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTJwMU[yO\|gh\|ryP	NYDN[W5uW0GQR1XS
A2058	NYjOXGZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\VTWM2OD1{LkG5Nlc6KM7:TR?=	M1;FUnNCVkeHUh?=
NB7	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TI[2lEPTB;Mj6zOFA5PiEQvF2=	MkjrV2FPT0WU
DOK	M{LNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWH5b\|JDUUN3ME2yMlM2Pzd\|IN88US=>	NWDH[oVyW0GQR1XS
CAL-27	NXTBNpZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTJwM{myN\|Yh\|ryP	MYnTRW5ITVJ?
BB65-RCC	M2rTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfNTnViUUN3ME2yMlQxPjd2IN88US=>	MWfTRW5ITVJ?
RD	MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M375ZWlEPTB;Mj60OFczOyEQvF2=	MWHTRW5ITVJ?
KNS-62	NWfUe21NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTJwNUGxOlQh\|ryP	NX[2S5lnW0GQR1XS
EW-13	Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NED2emhKSzVyPUKuOVY{OzlizszN	MlPuV2FPT0WU
DB	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTKTWM2OD1{LkW4O\|g5KM7:TR?=	MUXTRW5ITVJ?
HCC2218	NGTw[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF71[ZdKSzVyPUKuOlQ4PzhizszN	MYfTRW5ITVJ?
L-363	NYO0R25TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV:zd3FPUUN3ME2yMlc1OzdizszN	MoXsV2FPT0WU
CHL-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPQTWM2OD1{LkiwO\|g2KM7:TR?=	MXnTRW5ITVJ?
BFTC-905	NUSxfINJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;oTWM2OD1{LkiyOVMh\|ryP	NELpfZFUSU6JRWK=
HCE-T	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\hd2lEPTB;Mj64N\|I3PCEQvF2=	Mo\0V2FPT0WU
COLO-792	M1\nTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfUfXM{UUN3ME2yMlg1ODJ5IN88US=>	NWf2XoZsW0GQR1XS
LB2241-RCC	NFKzU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTJwOEW4PVMh\|ryP	MlX3V2FPT0WU
CAL-39	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXZdFhKSzVyPUKuPFk6QTlizszN	M{XYOXNCVkeHUh?=
T-24	MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnf2TWM2OD1{LkmxNVEzKM7:TR?=	M1TCc3NCVkeHUh?=
NCI-H727	Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nxNWlEPTB;Mj65NVc6PiEQvF2=	MULTRW5ITVJ?
Ca9-22	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3BTWM2OD1{Lkm3NlU2KM7:TR?=	MYnTRW5ITVJ?
MIA-PaCa-2	NEX3bVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTNwMEC3PFEh\|ryP	M4\5SnNCVkeHUh?=
HT-1080	NFiwXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nRb2lEPTB;Mz6wNVk6PyEQvF2=	MYPTRW5ITVJ?
D-423MG	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Ltd2lEPTB;Mz6wO\|c2OyEQvF2=	MVXTRW5ITVJ?
LAMA-84	NVvHdlZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TMPWlEPTB;Mz6xN\|U5KM7:TR?=	MkT0V2FPT0WU
SW780	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHZTWM2OD1\|LkG0NlI6KM7:TR?=	NEPwfopUSU6JRWK=
KU-19-19	NIm3NXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;4Tm9mUUN3ME2zMlE4ODN2IN88US=>	MUHTRW5ITVJ?
COLO-741	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlz0TWM2OD1\|LkG4Olc{KM7:TR?=	MljNV2FPT0WU
HSC-3	Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTNwMkOxOVEh\|ryP	NUXBXnVHW0GQR1XS
SN12C	NIH3PFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PBOGlEPTB;Mz6yOFcxOSEQvF2=	Mlq2V2FPT0WU
786-0	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV2ySmluUUN3ME2zMlI4OjR\|IN88US=>	NHnkWoRUSU6JRWK=
GAK	M2\BZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTNwM{K1OlEh\|ryP	NFXoUHBUSU6JRWK=
PANC-03-27	M3vZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV24cYE3UUN3ME2zMlM2ODR3IN88US=>	M4q2dHNCVkeHUh?=
CTB-1	M1Lsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPZTWM2OD1\|LkS3NFQ4KM7:TR?=	NYjXNW9sW0GQR1XS
A427	MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzieZlUUUN3ME2zMlU6PTV4IN88US=>	NIO0OYFUSU6JRWK=
EGI-1	M17ET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTNwNkC1PFMh\|ryP	NXfJSpBQW0GQR1XS
U-2-OS	NYm1dpdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4SybGlEPTB;Mz62O\|I2PiEQvF2=	MXHTRW5ITVJ?
NCI-SNU-5	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXntO2Y{UUN3ME2zMlY4PzNizszN	NHL4WWFUSU6JRWK=
SK-LU-1	NEKzVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTNwNki3PVgh\|ryP	MlrVV2FPT0WU
697	MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTNwNkm2NFMh\|ryP	MkjGV2FPT0WU
HPAF-II	NFjFRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TmdWlEPTB;Mz63OVQ6KM7:TR?=	MYXTRW5ITVJ?
NCI-H2087	NHXU[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7ofZZKSzVyPUOuPFQ3PzJizszN	M3\DbHNCVkeHUh?=
SK-MEL-3	NETufHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LBfmlEPTB;Mz64OVE2PCEQvF2=	NELPOm9USU6JRWK=
CGTH-W-1	NYi3PXVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknKTWM2OD1\|Lki1O\|I2KM7:TR?=	NXf4ZmVqW0GQR1XS
8505C	NIDJbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPVTYFsUUN3ME2zMlkxODd6IN88US=>	M3TpfXNCVkeHUh?=
GAMG	M4nBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTRwMEKzO\|ch\|ryP	M1qzdXNCVkeHUh?=
SW626	M33BbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTRwMES0PEDPxE1?	NHLWTmRUSU6JRWK=
CAL-62	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\WdWtKSzVyPUSuNFc1OyEQvF2=	MX3TRW5ITVJ?
MHH-PREB-1	M3HMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4X3[mlEPTB;ND6xNlEyOSEQvF2=	M{PuT3NCVkeHUh?=
RPMI-7951	MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTRwMkW1PFkh\|ryP	NWWxTohGW0GQR1XS
HOP-92	NInYbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTRwMkW2O{DPxE1?	M4jMe3NCVkeHUh?=
MDA-MB-231	Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDMWWtwUUN3ME20MlI6OjJ\|IN88US=>	NVL0RYhyW0GQR1XS
LAN-6	NEXqNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTRwM{G2N\|ch\|ryP	MnzqV2FPT0WU
ALL-PO	M4SyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTRwM{[xOVYh\|ryP	NEfyZXNUSU6JRWK=
HH	NIrTOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1L1ZmlEPTB;ND60NVU6PyEQvF2=	NX7mdZFEW0GQR1XS
IGROV-1	NUfyfpdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4GxXWlEPTB;ND60OVE4OSEQvF2=	MXTTRW5ITVJ?
NCI-H358	Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETwfG5KSzVyPUSuOFU{QDVizszN	MmLkV2FPT0WU
NB5	M3XDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDFTWM2OD12Lk[wN\|Y6KM7:TR?=	M3TjR3NCVkeHUh?=
NCI-H747	NUmwTGZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnT1TWM2OD12Lk[4PFA4KM7:TR?=	MV7TRW5ITVJ?
NH-12	MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTib3RKSzVyPUSuO\|E3OjVizszN	MXfTRW5ITVJ?
LB1047-RCC	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPifmJKSzVyPUSuO\|M5OTVizszN	Mm\OV2FPT0WU
EFO-27	MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;ubGlEPTB;ND63PFY3PyEQvF2=	MofJV2FPT0WU
EPLC-272H	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIK5bpJKSzVyPUSuPVk3PjlizszN	M3PpRXNCVkeHUh?=
CAL-54	NF\mdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTVwMEK2PVUh\|ryP	MnjiV2FPT0WU
H4	NWniTWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTVwMESyOVUh\|ryP	Ml\zV2FPT0WU
MOLT-13	NV7Cb5NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHMTWM2OD13LkC2O\|c3KM7:TR?=	MYXTRW5ITVJ?
CAL-33	NH7YfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFP5cIJKSzVyPUWuNVI{OTdizszN	NIj4[WZUSU6JRWK=
23132-87	NH70WodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTVwMU[4O\|Ih\|ryP	NUXq[pFLW0GQR1XS
UM-UC-3	NFzETZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHpRnI3UUN3ME21MlE5ODR5IN88US=>	MnPUV2FPT0WU
HuH-7	NFTkZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTQbXg{UUN3ME21MlI4OTR5IN88US=>	NG[4NIZUSU6JRWK=
BCPAP	M1Sxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TtS2lEPTB;NT6zNlk3QSEQvF2=	NXm0[3R{W0GQR1XS
AsPC-1	NGDzOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ToVmlEPTB;NT6zOlc3OyEQvF2=	NWfY[pBoW0GQR1XS
NCI-H1155	NF[1eXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTVwNECwOVEh\|ryP	MYnTRW5ITVJ?
GT3TKB	NHnxOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTVwNE[1PVgh\|ryP	NYfhUYtSW0GQR1XS
HCC2998	NIPSUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVO3[FVsUUN3ME21MlQ6OTB7IN88US=>	M2\XTnNCVkeHUh?=
NUGC-3	NXGzXodnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjvSHJKSzVyPUWuOFk{ODJizszN	NVTETpBqW0GQR1XS
Hs-578-T	NYjFNJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzCPFlTUUN3ME21MlU{Pzl2IN88US=>	NXTI[3hbW0GQR1XS
FADU	NF6xVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTwdXVtUUN3ME21MlU2PzJ4IN88US=>	MULTRW5ITVJ?
NBsusSR	M4fSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTVwNUexOVUh\|ryP	M{jrdHNCVkeHUh?=
ME-180	M3fTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTVwNUiwPVIh\|ryP	NYDQXVZvW0GQR1XS
SW1710	NGrJVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zs[GlEPTB;NT62NVY2PCEQvF2=	MmPmV2FPT0WU
HuP-T3	NVi4dXRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjlcpZKSzVyPUWuOlIxOjlizszN	NXjTWYFRW0GQR1XS
HOS	MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXP4XpJwUUN3ME21MlYzQTJ\|IN88US=>	MXvTRW5ITVJ?
PA-1	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M131UWlEPTB;NT62OFI3PSEQvF2=	NXLESYFXW0GQR1XS
LU-99A	M4j6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTVwNk[0OVEh\|ryP	MXvTRW5ITVJ?
RS4-11	NGXoUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTVwNk[3O\|Uh\|ryP	NUf6SIx{W0GQR1XS
TE-8	NIC4O4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEW3R\|JKSzVyPUWuOlg2OzdizszN	M1PBW3NCVkeHUh?=
RERF-LC-MS	NUDnbmpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXuUIdKSzVyPUWuOlg5ODNizszN	NUTwWI5nW0GQR1XS
MEL-JUSO	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nIZmlEPTB;NT63N\|c5KM7:TR?=	MX7TRW5ITVJ?
SK-MES-1	NVz6dpdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTVwOEO1Nlgh\|ryP	MYTTRW5ITVJ?
D-263MG	M{Pv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkOxTWM2OD13Lki4N\|UyKM7:TR?=	NIPtbHhUSU6JRWK=
NB10	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTVwOEm0OkDPxE1?	NGLQN2xUSU6JRWK=
SK-HEP-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LRc2lEPTB;NT65N\|Q4OSEQvF2=	MYHTRW5ITVJ?
HT-29	M2LabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTVwOUixNVgh\|ryP	NWXoS3VXW0GQR1XS
KYSE-140	NI\UPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3NdphWUUN3ME22MlAzOTh{IN88US=>	NInxWodUSU6JRWK=
NCI-H1666	M2fnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTZwMEi0OlEh\|ryP	M{nhOXNCVkeHUh?=
NCI-H1304	M{C5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLuT4VJUUN3ME22MlE6QTRizszN	NXzWTG97W0GQR1XS
RPMI-8866	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\EVJlKSzVyPU[uNlE{OTNizszN	MXHTRW5ITVJ?
MV-4-11	M4XP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jFTWlEPTB;Nj6yN\|E6QSEQvF2=	NUXT[\|NYW0GQR1XS
A431	Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXDTWM2OD14LkK0Nlk3KM7:TR?=	M{jzTnNCVkeHUh?=
PANC-10-05	NYfRVmo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13jTGlEPTB;Nj6yPFM3OyEQvF2=	MWDTRW5ITVJ?
TK10	M{SzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXS2TZR[UUN3ME22MlMzPjB2IN88US=>	Ml3qV2FPT0WU
NCI-H1975	NHXRbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTZwNEeyNVUh\|ryP	NVfYcJliW0GQR1XS
A172	M{H6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\HfppKSzVyPU[uOFkyPzZizszN	M3SwV3NCVkeHUh?=
D-566MG	M2i1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHYTWM2OD14LkW0N\|A{KM7:TR?=	M2\PcnNCVkeHUh?=
NCI-H2122	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV[xb2RpUUN3ME22MlYyPTJ6IN88US=>	MWfTRW5ITVJ?
COR-L105	NYT2ZlJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvnTWM2OD14Lk[1Nlc2KM7:TR?=	NYGyWIZIW0GQR1XS
AN3-CA	NIX5Zo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\DRZpUUUN3ME22MlY5PjRzIN88US=>	M3HEcXNCVkeHUh?=
Calu-6	Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTZwN{m2PVgh\|ryP	MkL1V2FPT0WU
HCT-116	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O3cWlEPTB;Nj64NVI3PCEQvF2=	NEe2[ZlUSU6JRWK=
MHH-NB-11	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTSTWM2OD14Lki1NFAzKM7:TR?=	NGXle3RUSU6JRWK=
MFE-280	NWrwN21yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTZwOEW5PFMh\|ryP	MYHTRW5ITVJ?
SW1088	NVzvS3ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEW4[FZKSzVyPU[uPVE6OTNizszN	MXfTRW5ITVJ?
SW48	NGXFVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPXTWM2OD14Lkm0OVEh\|ryP	MoDjV2FPT0WU
HuCCT1	M2WwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PLT2lEPTB;Nz6wNVA{PyEQvF2=	MVHTRW5ITVJ?
ACHN	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTdwMEK5OFMh\|ryP	MVvTRW5ITVJ?
8305C	NEjFZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\WTWM2OD15LkC5PVk2KM7:TR?=	NXfsPHV6W0GQR1XS
DoTc2-4510	M4ixemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T2TWlEPTB;Nz6xNlE2KM7:TR?=	NWDkPVJQW0GQR1XS
COR-L23	NXvtWWVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrN[2dKSzVyPUeuNlQ1OiEQvF2=	MoDJV2FPT0WU
SK-MEL-30	NE\ITJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTdwMkWwPFMh\|ryP	MnnOV2FPT0WU
BE-13	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\BbFZKSzVyPUeuN\|M5OzRizszN	MlnRV2FPT0WU
GR-ST	M1HtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTdwNECxO\|Qh\|ryP	M3nOe3NCVkeHUh?=
LU-135	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\WcmlEPTB;Nz61OVk{QSEQvF2=	M2XJPXNCVkeHUh?=
U-266	NVvIfJo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTdwNU[yPFYh\|ryP	MX;TRW5ITVJ?
NCI-H1355	NHq3NWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTUTWM2OD15LkW4OlM2KM7:TR?=	NGLlcVhUSU6JRWK=
NB14	NGXnWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofSTWM2OD15Lk[2OlQzKM7:TR?=	NELDfHRUSU6JRWK=
SCC-25	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHRNXI4UUN3ME23MlcxQSEQvF2=	MkLQV2FPT0WU
COLO-678	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjoTWM2OD15LkexNFc3KM7:TR?=	NVi2OGJpW0GQR1XS
TGBC1TKB	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfQRYtCUUN3ME23Mlg6Ozl6IN88US=>	NXPzO4RrW0GQR1XS
IST-MEL1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7yWo11UUN3ME24MlAxPDB4IN88US=>	NEm0epRUSU6JRWK=
ECC10	NGLzVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfhR4FQUUN3ME24MlA{Ozl3IN88US=>	M{jRWHNCVkeHUh?=
EW-16	M{Hndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mny1TWM2OD16LkC4OFQ2KM7:TR?=	MoGxV2FPT0WU
DOHH-2	MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmj6TWM2OD16LkKwNFk2KM7:TR?=	M4r5fXNCVkeHUh?=
NCI-H1581	NWXISlhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrubpRnUUN3ME24MlI3OzJ\|IN88US=>	MnW1V2FPT0WU
TE-5	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NES1cVVKSzVyPUiuOFI1OjlizszN	NVjzfWFtW0GQR1XS
CAKI-1	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDRdZFKSzVyPUiuOVczOjJizszN	MUTTRW5ITVJ?
A673	NHW3dZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MluwTWM2OD16Lk[zNlAzKM7:TR?=	NYq2WHp4W0GQR1XS
CAL-12T	NET2U2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnZT4ZKSzVyPUiuOlU4PTNizszN	MlnvV2FPT0WU
DBTRG-05MG	M1jLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG[wTIFKSzVyPUiuO\|Q5PTlizszN	MmHwV2FPT0WU
SK-N-FI	MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXGXmdKSzVyPUiuPFE{PzlizszN	MYfTRW5ITVJ?
K-562	NWDD[lVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2m4VGlEPTB;OD64N\|k2PyEQvF2=	NYm2Tnc1W0GQR1XS
SBC-1	NELvXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrad5hWUUN3ME24Mlg3PjR3IN88US=>	MXrTRW5ITVJ?
ES4	M1LhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\nTWM2OD16Lki2PFg1KM7:TR?=	M1XTSXNCVkeHUh?=
MS-1	NYDHdG84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRThwOEe1NVch\|ryP	MlL1V2FPT0WU
RKO	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLCSmh7UUN3ME24Mlg6ODV5IN88US=>	MlfmV2FPT0WU
NCI-H1693	Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fQc2lEPTB;OD65NlE4KM7:TR?=	NIq4V5NUSU6JRWK=
SW954	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;xe5VRUUN3ME24Mlk3QTd6IN88US=>	MnP0V2FPT0WU
SK-UT-1	M1vDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRThwOUe2PFMh\|ryP	MV7TRW5ITVJ?
T98G	Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moq1TWM2OD16Lkm5PFQ3KM7:TR?=	NVPwdYhkW0GQR1XS
NCI-H2126	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTyO4NKSzVyPUmuNFA5OjZizszN	Ml3mV2FPT0WU
TE-12	M1j5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4WxS2lEPTB;OT6wN\|M3PyEQvF2=	NFrKNm9USU6JRWK=
DK-MG	NIL2TmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;hbG9FUUN3ME25MlIyOTlzIN88US=>	NEjJT2ZUSU6JRWK=
MEG-01	NIDDToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXWTWJKSzVyPUmuNlQ6OzFizszN	MkfuV2FPT0WU
HCC1937	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rnbWlEPTB;OT6yPVA6OSEQvF2=	NY\ZOVRNW0GQR1XS
MKN45	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fOSGlEPTB;OT60OVA3PSEQvF2=	NFX5Z\|VUSU6JRWK=
NCI-H1792	M3L1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlO2TWM2OD17LkS1NlE6KM7:TR?=	NGXs[3FUSU6JRWK=
SW1417	MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTlwNU[4N\|ch\|ryP	M2L0RnNCVkeHUh?=
639-V	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzsWY1KSzVyPUmuOlQ{QDhizszN	NGK5WZdUSU6JRWK=
P30-OHK	NH7PSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHx[oVNUUN3ME25MlY2OzF4IN88US=>	M2\6VnNCVkeHUh?=
YKG-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjrU5dXUUN3ME25Mlc2ODN\|IN88US=>	NHzDZolUSU6JRWK=
KGN	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDFVmJXUUN3ME25Mlg{Pzl3IN88US=>	MmXRV2FPT0WU
MSTO-211H	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DyXmlEPTB;OT65OVUzQSEQvF2=	Mn7iV2FPT0WU
NCI-H1573	M2XuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTFyLkG1O\|Qh\|ryP	M1S0THNCVkeHUh?=
NCI-H720	NYW1fnhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;ocGlEPTB;MUCuNVk5QSEQvF2=	MX\TRW5ITVJ?
KARPAS-45	NWnmcoxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvrVIdKSzVyPUGwMlI4QTVizszN	M1rMR3NCVkeHUh?=
MDA-MB-175-VII	M2LFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnoTHhKSzVyPUGwMlQ5KM7:TR?=	MV;TRW5ITVJ?
SK-NEP-1	M{[0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTFyLkS5PFEh\|ryP	Mk[3V2FPT0WU
MKN28	Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWr4dG06UUN3ME2xNE42OThizszN	NE\RWZJUSU6JRWK=
KYSE-520	M4DFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrHUWdKSzVyPUGwMlUzKM7:TR?=	MoPYV2FPT0WU
KE-37	Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\0UnhKSzVyPUGwMlUzPzJizszN	MmrQV2FPT0WU
VA-ES-BJ	MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTFyLkW2O{DPxE1?	NIjDWWVUSU6JRWK=
CCRF-CEM	NGmzcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTFyLkW2PFQh\|ryP	MlLyV2FPT0WU
GMS-10	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\LTWM2OD1zMD62NFk1KM7:TR?=	M4TQVnNCVkeHUh?=
NCI-H1623	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnNXIdiUUN3ME2xNE43Ozd7IN88US=>	NWmxcWE1W0GQR1XS
NEC8	NELjfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\oelQzUUN3ME2xNE44Pzd\|IN88US=>	MYrTRW5ITVJ?
MOLT-16	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkT2TWM2OD1zMD64NVE{KM7:TR?=	MYnTRW5ITVJ?
DJM-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHVT\|lKSzVyPUGxMlA{PzlizszN	NGqyOXJUSU6JRWK=
U251	NXuzc3RET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDFTWM2OD1zMT6wOFIh\|ryP	M2T1e3NCVkeHUh?=
SBC-5	NHrsS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjBNHFUUUN3ME2xNU4yPDZ5IN88US=>	M1n2T3NCVkeHUh?=
SW756	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;TbJFxUUN3ME2xNU4zOTV2IN88US=>	NFLifohUSU6JRWK=
KS-1	MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Lz[WlEPTB;MUGuNlYyQSEQvF2=	MVjTRW5ITVJ?
SF295	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTFzLkOxNFQh\|ryP	MYTTRW5ITVJ?
YH-13	NYnTNVR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTFzLkOyOlch\|ryP	NWfYVY5IW0GQR1XS
SW837	NIPvOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTFzLkO1NFYh\|ryP	NYn0RpJDW0GQR1XS
KYSE-450	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3v3fmlEPTB;MUGuOFA2PyEQvF2=	MUfTRW5ITVJ?
KYSE-180	M3LIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTFzLkS4NkDPxE1?	MXnTRW5ITVJ?
S-117	M17idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHHfJd1UUN3ME2xNU41QDl4IN88US=>	MnqxV2FPT0WU
KOSC-2	MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jNNGlEPTB;MUGuOlIzOiEQvF2=	M3fobHNCVkeHUh?=
KYSE-270	NGDXOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTFzLki3OFUh\|ryP	MV7TRW5ITVJ?
D-336MG	M4e4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTFzLkmwO\|Uh\|ryP	NE\UeGJUSU6JRWK=
KALS-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDv[IpTUUN3ME2xNk4xODF4IN88US=>	NGO3RnFUSU6JRWK=
LB373-MEL-D	MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLSZ5ZrUUN3ME2xNk4xPTN\|IN88US=>	MXjTRW5ITVJ?
HLE	M{fufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTF{LkC1PFUh\|ryP	MmmzV2FPT0WU
SJSA-1	MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXE[4xyUUN3ME2xNk4xPzN3IN88US=>	M3HVTHNCVkeHUh?=
SW1990	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTF{LkC5NVEh\|ryP	NXXyfXcxW0GQR1XS
NOS-1	NYfjXJFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVThZWR4UUN3ME2xNk4yOzV{IN88US=>	MoTXV2FPT0WU
GI-ME-N	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M360O2lEPTB;MUKuNlE3OyEQvF2=	NV;KXpFrW0GQR1XS
NCI-H1703	NF7IeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nDO2lEPTB;MUKuNlYyPiEQvF2=	MWTTRW5ITVJ?
ES7	M3q3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljKTWM2OD1zMj6yO\|I1KM7:TR?=	M{TLbnNCVkeHUh?=
KYSE-510	NWTp[nRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLyS5NJUUN3ME2xNk42ODd7IN88US=>	MoH4V2FPT0WU
BHY	NUSwcFk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHoTWM2OD1zMj61N\|A4KM7:TR?=	M1TKPHNCVkeHUh?=
TCCSUP	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHwSopKSzVyPUGyMlU4PTdizszN	MVfTRW5ITVJ?
HSC-2	MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvzTWM2OD1zMj61PVk3KM7:TR?=	NH3lOWZUSU6JRWK=
BEN	NHz4cZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfZUGFPUUN3ME2xNk43OTR\|IN88US=>	MUTTRW5ITVJ?
769-P	MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPjTWM2OD1zMj63PVI1KM7:TR?=	MVLTRW5ITVJ?
HT	M{XZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rMeWlEPTB;MUKuPFM1PiEQvF2=	NYTZNoFYW0GQR1XS
LXF-289	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoH4TWM2OD1zMj65OVMyKM7:TR?=	NI\kRXRUSU6JRWK=
OVCAR-3	NUHV[Wo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLLTWM2OD1zMj65OVY4KM7:TR?=	NFr6WZJUSU6JRWK=
ATN-1	NWjUdXpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jYNWlEPTB;MUOuNFE5PCEQvF2=	MoTkV2FPT0WU
8-MG-BA	Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIOwVYRKSzVyPUGzMlA1PTVizszN	MVPTRW5ITVJ?
SW13	MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmi3TWM2OD1zMz6xNVY2KM7:TR?=	MlLDV2FPT0WU
NCI-H1092	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn0TWM2OD1zMz6xOlIh\|ryP	NYnBdoF5W0GQR1XS
OAW-42	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jwd2lEPTB;MUOuNVk{PyEQvF2=	MlvkV2FPT0WU
NCI-H2452	M3vKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTF\|LkKxO\|Uh\|ryP	MmizV2FPT0WU
CAPAN-1	Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTF\|LkW1NVQh\|ryP	M2TZfnNCVkeHUh?=
NCI-H2009	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DoZWlEPTB;MUOuOVkyQSEQvF2=	Ml\xV2FPT0WU
SF268	M3XwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7uWHd5UUN3ME2xN{43OzJ4IN88US=>	M3r1SHNCVkeHUh?=
GCIY	NVXEZ2J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzQTWM2OD1zMz62PVI4KM7:TR?=	MmPWV2FPT0WU
OS-RC-2	M4n6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGO4S5lKSzVyPUGzMlk2ODFizszN	M132THNCVkeHUh?=
GCT	NF;KbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHDXlFKSzVyPUGzMlk3QTdizszN	MnPIV2FPT0WU
NB17	MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTG[JF[UUN3ME2xOE4xQDVizszN	NIWwfpRUSU6JRWK=
NCI-H2030	NH;ocppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3PcpRKSzVyPUG0MlE1PjVizszN	M2WxVnNCVkeHUh?=
HC-1	NFrwbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4r4NGlEPTB;MUSuNlA5PyEQvF2=	MXjTRW5ITVJ?
QIMR-WIL	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\6XWlEPTB;MUSuN\|QyOiEQvF2=	MljtV2FPT0WU
Capan-2	NGnTUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3tR2tKSzVyPUG0MlM4OTRizszN	MlPKV2FPT0WU
BALL-1	NVLudlJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTF2LkS2OlUh\|ryP	M3j5fHNCVkeHUh?=
LS-1034	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUm5WW9CUUN3ME2xOE43OTV{IN88US=>	NFjCN4VUSU6JRWK=
U-118-MG	NEPGOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTF2Lk[zNUDPxE1?	NVHsd4ZjW0GQR1XS
NCI-H630	Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1r4OmlEPTB;MUSuOlU3QCEQvF2=	MXTTRW5ITVJ?
OVCAR-8	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Xre2lEPTB;MUSuO\|IxOSEQvF2=	NGfnWYhUSU6JRWK=
NCI-H2347	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTF2LkiyN{DPxE1?	NYjIe5d2W0GQR1XS
BT-549	NELDcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTF2LkiyPFQh\|ryP	M3W0[3NCVkeHUh?=
LB831-BLC	NWD0dlNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGKzTVlKSzVyPUG0Mlg6OzRizszN	MojjV2FPT0WU
NCI-H661	NV;5fWNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTF2Lkm1PUDPxE1?	M3\ub3NCVkeHUh?=
MKN7	M1PKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvJOJVWUUN3ME2xOU4xODl\|IN88US=>	NXLROI0yW0GQR1XS
U-87-MG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnDfYpXUUN3ME2xOU4xQDl5IN88US=>	M1zhWXNCVkeHUh?=
OVCAR-4	NYnTOVJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vk[2lEPTB;MUWuNVQzPCEQvF2=	Mmn4V2FPT0WU
OE33	NVPGUXhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1mwfGlEPTB;MUWuNVcyOSEQvF2=	MVzTRW5ITVJ?
EC-GI-10	NI\meIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTQTWM2OD1zNT6yN\|U4KM7:TR?=	Mo\pV2FPT0WU
AM-38	NF7COWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HaT2lEPTB;MUWuNlcyPyEQvF2=	MX3TRW5ITVJ?
NCI-H1563	M3LydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HKO2lEPTB;MUWuN\|Q6KM7:TR?=	Ml3OV2FPT0WU
SCC-4	NFu1TY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;vTWM2OD1zNT60NVA{KM7:TR?=	NFvwSJFUSU6JRWK=
Detroit562	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXsTWM2OD1zNT60OVQ4KM7:TR?=	MnPGV2FPT0WU
PC-14	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXCXmFKSzVyPUG1MlQ5PjZizszN	NUW0NWw5W0GQR1XS
ES3	NFOyc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjEbnFKSzVyPUG1MlU{PiEQvF2=	MVPTRW5ITVJ?
OCI-AML2	NXTFV4NET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTF3Lke2NVQh\|ryP	MoLzV2FPT0WU
LU-134-A	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInmb3RKSzVyPUG1MlkxOThizszN	NGfoZ4xUSU6JRWK=
SAS	NVXwWlZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ToPGlEPTB;MUWuPVM4OyEQvF2=	M{PNb3NCVkeHUh?=
TGBC11TKB	NE\WNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPDVoNKSzVyPUG1Mlk1OTRizszN	MW\TRW5ITVJ?
HOP-62	NWH1TFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWewc3p3UUN3ME2xOU46PTl5IN88US=>	M1XOVnNCVkeHUh?=
G-401	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTF3Lkm2OFkh\|ryP	M2X5cXNCVkeHUh?=
NCI-H28	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HROWlEPTB;MU[uNFg2PiEQvF2=	Mk\4V2FPT0WU
A204	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3RWmpKSzVyPUG2MlIxODZizszN	MVrTRW5ITVJ?
NCI-H1299	M4DoVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTF4LkKyPVEh\|ryP	MlHEV2FPT0WU
VMRC-RCZ	NIXHdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzRcY9HUUN3ME2xOk4zPTl{IN88US=>	M1XlRnNCVkeHUh?=
BxPC-3	NXe4XHg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHze4FKSzVyPUG2MlI5PTZizszN	MorWV2FPT0WU
NCI-H2228	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTF4LkWxOVgh\|ryP	NXXD[GYxW0GQR1XS
NCI-H23	NU\GfXZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrSTJVKSzVyPUG2MlYxPzhizszN	NFPySFVUSU6JRWK=
NKM-1	NHS0N4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrmd4J3UUN3ME2xO{4xOTh7IN88US=>	MWfTRW5ITVJ?
KYSE-70	NWnjdYtMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLxcZZKSzVyPUG3MlI5QSEQvF2=	NGTQSZdUSU6JRWK=
BB49-HNC	NY\tR4pTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml76TWM2OD1zNz61Olg3KM7:TR?=	MXfTRW5ITVJ?
SCC-15	M2nwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDl[plwUUN3ME2xO{45PDd\|IN88US=>	NGjheHhUSU6JRWK=
D-247MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTF5LkmyOFch\|ryP	NEf0T45USU6JRWK=
BB30-HNC	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;CXVR5UUN3ME2xPE4xOzF6IN88US=>	NU[0PZNyW0GQR1XS
CAL-85-1	Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHlNWxKSzVyPUG4MlE5ODlizszN	NYriSms2W0GQR1XS
HT-3	NU\n[ZE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTF6LkO5O\|ch\|ryP	NXnZbZd4W0GQR1XS
KYSE-410	M{LKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYH3e\|RPUUN3ME2xPE41PTd5IN88US=>	M3n5bHNCVkeHUh?=
SW982	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDScI5IUUN3ME2xPE42PjR7IN88US=>	NUD0R3RLW0GQR1XS
SW962	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIG4WmJKSzVyPUG4MlU4ODJizszN	MW\TRW5ITVJ?
Ramos-2G6-4C10	NGDYd\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTF6LkW5Nlch\|ryP	MmXvV2FPT0WU
OC-314	M3rv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVH6N5BUUUN3ME2xPE44Ozh2IN88US=>	MnnaV2FPT0WU
LS-123	NGLGW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XVe2lEPTB;MUiuO\|kxOSEQvF2=	NYfRZnBUW0GQR1XS
D-502MG	NXjB[m5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFO1WpZKSzVyPUG4MlgyOzlizszN	NXfHXlV4W0GQR1XS
RO82-W-1	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFH6[nJKSzVyPUG4MlgzQDhizszN	MmiyV2FPT0WU
HuO9	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTF7LkGzO\|kh\|ryP	NX;NPIRHW0GQR1XS
ETK-1	NH3aWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3ZVoFKSzVyPUG5MlE5OjdizszN	NFi1bG1USU6JRWK=
SNU-387	MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELodHJKSzVyPUG5MlE5QDlizszN	MofuV2FPT0WU
SW1573	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTF7LkG5Olkh\|ryP	NXe0VJlVW0GQR1XS
NTERA-S-cl-D1	M1mzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTTTWM2OD1zOT6yNFA4KM7:TR?=	M37XeHNCVkeHUh?=
SF126	NVq4fWlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4r1WGlEPTB;MUmuN\|UxOiEQvF2=	NHXPWGVUSU6JRWK=
Calu-3	NWTqdodjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXtW4pVUUN3ME2xPU41OjN5IN88US=>	M4fEbHNCVkeHUh?=
NCI-H1048	NUPLTllST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\kN\|FKSzVyPUKwMlMzPjZizszN	NXfIcoZrW0GQR1XS
NCI-H226	NWrzXmFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXETWM2OD1{MD60N\|k6KM7:TR?=	MmrMV2FPT0WU
FTC-133	NHXs[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVO5cZBIUUN3ME2yNE41PzB\|IN88US=>	MlHNV2FPT0WU
SF539	NYntO5pnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LEPWlEPTB;MkCuOVE4OiEQvF2=	MkCzV2FPT0WU
TE-6	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTJyLkiwOlch\|ryP	NWjkV2NMW0GQR1XS
UMC-11	NWO1Rm1ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTJyLkmxOlQh\|ryP	Mn7DV2FPT0WU
Becker	M2PWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEH4c2ZKSzVyPUKxMlEyOThizszN	NFHneWhUSU6JRWK=
KP-4	NWrnbnV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTJzLkGxPVYh\|ryP	MYLTRW5ITVJ?
ChaGo-K-1	NUTHRmxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjNOYdKSzVyPUKxMlM3OjdizszN	NXn1[Gh4W0GQR1XS
CFPAC-1	M3foOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mon5TWM2OD1{MT6zPFU5KM7:TR?=	MX7TRW5ITVJ?
A498	NFHYOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHoSVJKSzVyPUKxMlU{OTJizszN	M1q0V3NCVkeHUh?=
NCI-H1755	MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvMd5lKSzVyPUKxMlY4PDFizszN	NGDmb3VUSU6JRWK=
TI-73	MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmm1TWM2OD1{Mj6zNlgh\|ryP	M2rvTnNCVkeHUh?=
NCI-H441	M4rPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIWzc4VKSzVyPUKyMlU3QDlizszN	NHXpUpBUSU6JRWK=
CaR-1	MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fjPGlEPTB;MkOuNFIyOyEQvF2=	MX\TRW5ITVJ?
HCC1806	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofQTWM2OD1{Mz6wOVg{KM7:TR?=	MlTGV2FPT0WU
SNU-449	NX7heGU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfZTWM2OD1{Mz6zNlkh\|ryP	M1XENXNCVkeHUh?=
EKVX	NXm2bG95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYr5XmlOUUN3ME2yN{4{QTB7IN88US=>	MWTTRW5ITVJ?
DMS-114	NF3DNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DnWmlEPTB;MkOuOVc3PSEQvF2=	M2XXTXNCVkeHUh?=
A704	Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S5NGlEPTB;MkOuOlExOyEQvF2=	NVjCRnJMW0GQR1XS
LC-2-ad	NIW5e2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknaTWM2OD1{Mz62NVQ4KM7:TR?=	NFftR\|hUSU6JRWK=
VM-CUB-1	NWS0[Zp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\jdJVKSzVyPUKzMlc{PDFizszN	MoqwV2FPT0WU
PC-3	NVXZO4hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;HT2lEPTB;MkSuNFUzPiEQvF2=	M1vaNHNCVkeHUh?=
HEL	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFv3R4VKSzVyPUK0MlA5PjVizszN	M3LPSHNCVkeHUh?=
ABC-1	NFr5cIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTJ2LkK3Nlkh\|ryP	MnmzV2FPT0WU
COLO-680N	NWr0WnBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTJ2LkS3OlQh\|ryP	MlPTV2FPT0WU
MZ1-PC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rmW2lEPTB;MkSuOlg4KM7:TR?=	MnvZV2FPT0WU
NCI-H69	MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXQTWM2OD1{ND63N\|U1KM7:TR?=	NVPwOGs5W0GQR1XS
TE-1	M{PH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjPTWM2OD1{NT6wOFk6KM7:TR?=	MWjTRW5ITVJ?
EW-3	NGrjTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;M[JpKSzVyPUK1MlEyOyEQvF2=	MlHSV2FPT0WU
PANC-08-13	M3TY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfmTWM2OD1{NT64NVA{KM7:TR?=	MW\TRW5ITVJ?
NMC-G1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTJ4LkCwPFgh\|ryP	MVzTRW5ITVJ?
BT-20	M{TUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTJ4LkS1OFMh\|ryP	NF;se5JUSU6JRWK=
TGBC24TKB	M2XLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFe2SG5KSzVyPUK2Mlc{OzFizszN	MnrOV2FPT0WU
TE-11	NHHaN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTJ4Lkm4PVUh\|ryP	MmK0V2FPT0WU
ESS-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELtW2JKSzVyPUK3MlMzOTZizszN	M3\Jd3NCVkeHUh?=
JVM-3	NHO4e29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPafm5KSzVyPUK3MlY1PzVizszN	MVfTRW5ITVJ?
C3A	NHr3W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLIfIVKSzVyPUK3Mlg1QTZizszN	NVrSfoR[W0GQR1XS
MDA-MB-157	M4j1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJ5Lki3OVMh\|ryP	NYXwWHF2W0GQR1XS
KLE	NX7ONZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFG4No1KSzVyPUK4MlExPThizszN	NUj3VIhpW0GQR1XS
ES1	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjme5BKSzVyPUK4MlE5OzhizszN	Mn[4V2FPT0WU
CAL-120	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTJ6LkO5PVkh\|ryP	M3;0R3NCVkeHUh?=
NCI-N87	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTJ6LkWxNFUh\|ryP	NH\Q[YZUSU6JRWK=
RPMI-8226	NUjRW4luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHZ[pd5UUN3ME2yPU4yQDR\|IN88US=>	MorZV2FPT0WU
COR-L88	NIjNc\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGyc2U1UUN3ME2yPU4zPDF7IN88US=>	Ml3MV2FPT0WU
UACC-893	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTJ7LkOxN\|ch\|ryP	NYfhOGp6W0GQR1XS
C8166	NGPoVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2C4d2lEPTB;MkmuPVk6PiEQvF2=	MUjTRW5ITVJ?
J82	NVL2VY5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\LRm0zUUN3ME2zNE45OTR5IN88US=>	NUXTWnZDW0GQR1XS
PFSK-1	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXpXmxmUUN3ME2zNU4xPjV7IN88US=>	MlvwV2FPT0WU
COLO-684	NV7HOGQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;rR2lEPTB;M{GuOFM4PCEQvF2=	MYrTRW5ITVJ?
CAL-72	NHj4TIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTLTWM2OD1\|MT61O\|I6KM7:TR?=	Mn\HV2FPT0WU
SNB75	MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfu[ZlKSzVyPUOxMlg6PyEQvF2=	NGjQd5ZUSU6JRWK=
MDA-MB-415	M3n1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjoTWM2OD1\|MT65O\|YzKM7:TR?=	NYXnU4pnW0GQR1XS
SiHa	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTN{LkS3NVEh\|ryP	NEK2SXdUSU6JRWK=
NCI-H1648	M1iwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfj[YF6UUN3ME2zNk46OzR3IN88US=>	MXTTRW5ITVJ?
EFO-21	NFPqTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPJTGFKSzVyPUOzMlAxPSEQvF2=	M1vyS3NCVkeHUh?=
HCC38	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\jVHZKSzVyPUOzMlM5PDFizszN	MYjTRW5ITVJ?
IA-LM	NVP6UYU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTN\|Lke4PFkh\|ryP	M1;TeHNCVkeHUh?=
CTV-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLqTWM2OD1\|Mz65O\|g3KM7:TR?=	M3n4TXNCVkeHUh?=
NCI-H446	M1:5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TYbWlEPTB;M{SuNlY5QSEQvF2=	NY\m[oRKW0GQR1XS
IST-SL1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPUTWM2OD1\|ND63OFA5KM7:TR?=	MYnTRW5ITVJ?
EW-22	Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfYR\|NiUUN3ME2zOE44PzV7IN88US=>	M1\KfHNCVkeHUh?=
JEG-3	M{iwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDmTWM2OD1\|Nj6xO\|Y3KM7:TR?=	M4LMc3NCVkeHUh?=
LU-65	M1Lpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHLTWM2OD1\|Nj6yPVg2KM7:TR?=	MnvFV2FPT0WU
NCI-H596	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTN4Lkm1PVEh\|ryP	NYW1cnpwW0GQR1XS
KNS-81-FD	MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\p[pM5UUN3ME2zO{4yPDVizszN	NHuyXFlUSU6JRWK=
NCI-H1793	NXHDU4VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvMTWM2OD1\|Nz63NFg3KM7:TR?=	MV7TRW5ITVJ?
NCI-H460	M3\tSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDLVVhKSzVyPUO4MlA5PzNizszN	NFj4VIJUSU6JRWK=
MPP-89	M3zZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXBTWM2OD1\|OT61PFg3KM7:TR?=	M1f2b3NCVkeHUh?=
D-542MG	NYHZUXFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zHVWlEPTB;M{muPFQ{PiEQvF2=	NF\s[45USU6JRWK=
JAR	NH7FXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkf5TWM2OD12MD60O\|A2KM7:TR?=	MkDZV2FPT0WU
NCI-H209	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rSWGlEPTB;NECuOlc4KM7:TR?=	NY\PVYJtW0GQR1XS
G-402	M1Ticmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPqTWM2OD12MT6zPVk{KM7:TR?=	NH\4PWFUSU6JRWK=
IST-MES1	MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHWUplIUUN3ME20Nk4yQTN3IN88US=>	NEi2d2lUSU6JRWK=
Daoy	NWP5O3hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTR{LkW0O\|Eh\|ryP	MWHTRW5ITVJ?
EW-11	MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3YTWM2OD12Mz6xNlEyKM7:TR?=	MWLTRW5ITVJ?
Saos-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTR\|LkG1N\|ch\|ryP	NHPVN4FUSU6JRWK=
no-10	M3LKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmryTWM2OD12Mz6xO\|AzKM7:TR?=	MoPPV2FPT0WU
HCC1395	M2n4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\vT2lEPTB;NEOuOFY1PCEQvF2=	MkP2V2FPT0WU
HCE-4	NIi2U2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLufHFKSzVyPUSzMlc3PjRizszN	MX;TRW5ITVJ?
EW-1	NFnPWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVi2eXpOUUN3ME20N{45ODR7IN88US=>	M3;5bXNCVkeHUh?=
OCUB-M	NH7sNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYntSGlNUUN3ME20OE4{PjN6IN88US=>	MX;TRW5ITVJ?
IGR-1	MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYO0Sos5UUN3ME20OE41OTF3IN88US=>	NVqzT4x7W0GQR1XS
NCI-H1838	NYfGZ21nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzoUJhKSzVyPUS0MlQ{PDlizszN	Ml\uV2FPT0WU
NCI-H2405	NWTNcJBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XrUGlEPTB;NESuOVM1KM7:TR?=	MY\TRW5ITVJ?
GB-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTR2Lke0OlMh\|ryP	NV3tNWhwW0GQR1XS
MG-63	M1nuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHHc2lKSzVyPUS2MlA3QTZizszN	NILMdXlUSU6JRWK=
KP-N-YN	NIXUNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXBTWM2OD12Nj60Olc6KM7:TR?=	NIPj[2VUSU6JRWK=
no-11	NWrXTW9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTR5LkCyOFQh\|ryP	NEfLSYZUSU6JRWK=
SW948	M4Dodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TCWGlEPTB;NEeuN\|M4PyEQvF2=	MkO3V2FPT0WU
CAMA-1	NXj0UWhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1WybGlEPTB;NEeuN\|Q{QCEQvF2=	MoXPV2FPT0WU
HCC1187	NF;rd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jq[2lEPTB;NEeuOVEh\|ryP	NEPESnZUSU6JRWK=
D-392MG	M2\3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTR5Lk[1NVYh\|ryP	MoDkV2FPT0WU
647-V	NXP5eGtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTR7LkO0NVQh\|ryP	M1fVcHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo

Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. ^[1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. ^[2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. ^[5]

Protocol

Kinase Assay: ^[2]	+ Expand MEK1 Assay: MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl₂ /2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research: ^[1]	+ Expand Cell lines: Colon 26 carcinoma cells Concentrations: 0.1-10 μM Incubation Time: 24 hours Method: Cells are planted seeded in T-75 cm ² flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: PTC cells in athymic mice Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water Dosages: 150 mg/kg Administration: Orally twice daily (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	96 mg/mL (200.55 mM)
	Ethanol	14 mg/mL (29.24 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 For best results, use promptly after mixing.	10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD184352 (CI-1040) SDF

Molecular Weight	478.67
Formula	C₁₇H₁₄ClF₂IN₂O₂
CAS No.	212631-79-3
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00033384	Completed	Breast Cancer\|Colorectal Cancer\|Lung Cancer\|Pancreatic Cancer	University of Alabama at Birmingham\|National Cancer Institute (NCI)	February 2002	Phase 2
NCT00033384	Completed	Breast Cancer\|Colorectal Cancer\|Lung Cancer\|Pancreatic Cancer	University of Alabama at Birmingham\|National Cancer Institute (NCI)	February 2002	Phase 2
NCT00034827	Completed	Colorectal Neoplasms\|Breast Neoplasms\|Carcinoma Non-Small-Cell Lung\|Pancreatic Neoplasms	Pfizer	January 2002	Phase 2
NCT00034827	Completed	Colorectal Neoplasms\|Breast Neoplasms\|Carcinoma Non-Small-Cell Lung\|Pancreatic Neoplasms	Pfizer	January 2002	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Selective MEK Inhibitor

Selumetinib (AZD6244) : MEK1-selective, IC50=14 nM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products4

Cobimetinib (GDC-0973, RG7420) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

Features:More potent than PD0325901 or AZD6244.
PD0325901

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Features:Does not inhibit c-Raf phosphorylated MEK1.
Binimetinib (MEK162, ARRY-162, ARRY-438162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Refametinib (RDEA119, Bay 86-9766)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 48 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 48 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)